Fragmin

Unstable angina, Pulmonary embolism, Deep-vein thrombosis, Prophylaxis of clotting in extracorporeal circulation in haemodialysis or haemofiltration, Prophylaxis of venous thromboembolism during surgery

Subcutaneous Venous thromboembolism Adult: 200 U/kg daily as a single or in 2 divided doses in pregnant and high-risk patients. Max: 18,000 U/day. Patients w/ symptomatic thromboembolism and cancer: 200 U/kg once daily for 30 days, followed by 150 U/kg once daily for up to 5 mth; if chemotherapy induced thrombocytopenia develops, reduce dose to 2,500 U while platelet counts are below 100,000 cells/mm3, temporarily stop treatment if platelet counts are below 50,000 cells/mm3. Prophylaxis of venous thromboembolism during surgical procedures Adult: Moderate risk patients: 2,500 U given 1-2 hr before the procedure followed by 2,500 U once daily for 5-7 days or until the patient is fully ambulant. High risk patients: 2,500 U given 1-2 hr before and 8-12 hr after the procedure followed by 5,000 U daily. Alternatively, 5,000 U given in the evening before surgery followed by 5,000 U each subsequent evening for 5-10 days, or up to 5 wk after hip replacement surgery. Medical patients: 5,000 U once daily for 14 days or longer. Unstable angina Adult: 120 U/kg 12 hrly continued for 5-8 days w/ concomitant low-dose aspirin. Max: 10,000 U 12 hrly. For patients who require treatment longer than 8 days while awaiting revascularisation procedure: 5,000 U (7,500 U in men weighing ?70 kg and women weighing ?80 kg) 12 hrly for up to 45 days until the procedure is performed. Intravenous Prophylaxis of clotting in extracorporeal circulation in haemodialysis or haemofiltration Adult: 30-40 U/kg IV inj, followed by an IV infusion of 10-15 U/kg/hr. A single dose of 5,000 U may be given for haemodialysis or haemofiltration session lasting <4 hr. For patients at high risk of bleeding or in acute renal failure: 5-10 U/kg IV inj followed by an infusion of 4-5 U/kg/hr.

Safety & efficacy not established

Renal impairment: CrCl <30 mL/min: Dosage adjustment needed based on anti-Factor Xa activity.

Hypersensitivity. Active major bleeding, severe coagulation disorders; lumbar puncture; sympathetic block; brain, spinal cord, eye or ear surgery; severe hypertension.

Dalteparin sodium is a low molecular weight heparin analogue which inhibits factor Xa more than factor IIa (thrombin).

Preexisting thrombocytopenia, recent childbirth, DM, subacute bacterial endocarditis, pericarditis, recent lumbar puncture, vasculitis. Monitor coagulation time. Hepatic or renal dysfunction; high doses; osteoporosis; familial antithrombin III deficiency; elderly; children; platelet count and stool occult blood test recommended during treatment; GI ulceration. Pregnancy and lactation. Lactation: Enters breast milk; use with caution

1-10% Injection site hematoma (7-35%),Thrombocytopenia (10.9-13.6%, patients with cancer ),Injection site pain (4.5-12%),Major hemorrhage (up to 4.6%),Increased liver function test (up to 4.3%),Wound hematoma,Hematuria Frequency Not Defined Epidural hematoma,Spinal hematoma,Hemorrhagic cerebral infarction,Intracranial hemorrhage,Intrauterine subdural hemorrhage,Thrombocytopenia (<1%, non-cancer indications),Anaphylactoid reaction (rare) Potentially Fatal: Severe haemorrhage.

Pregnancy Available data have not reported a clear association with dalteparin and adverse developmental outcomes There are risks to the mother associated with untreated VTE in pregnancy, and a potential for adverse effects on the preterm infant when used in pregnancy Clinical considerations Published data describe that women with a previous history of VTE in pregnancy are at higher risk for recurrence during subsequent pregnancies compared to those with no risk factor for VTE Cases of “gasping syndrome” have occurred in premature infants when large amounts of benzyl alcohol have been administered (99-404 mg/kg/day) Multiple-dose 3.8 mL vials of dalteparin contain 14 mg/mL of benzyl alcohol Lactation Limited published data indicate that the drug is present in human milk in small amounts; no adverse effects on breastfed infant reported; there are no data on effects of drug on milk production; oral absorption of dalteparin is expected to be low, but clinical implications, if any, of this small amount of anticoagulant activity on a breastfed infant are unknown; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from the drug or from underlying maternal condition

Increased risk of haemorrhage w/ other anticoagulant/antiplatelet agents (e.g. aspirin/dipyridamole, glycoprotein IIb/IIIa receptor antagonists, vit K antagonists, NSAIDs, cytostatics, dextran, thrombolytics, sulfinpyrazone, probenecid, etacrynic acid). Reduced anticoagulant effect w/ antihistamines, cardiac glycosides, tetracycline and ascorbic acid.